Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,900.00-1.51%ETH$2,404.54-3.20%GOLD$4,387.30+1.26%OIL$103.71-2.00%
Smart Investors Daily
FU

NASDAQ · FULC

Fulcrum Therapeutics, Inc.

Healthcare · Biotechnology

$3.78

Down-$0.01 (-0.26%)

Updated Sep 16, 2026, 7:14 AM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
692.63M
P/E ratio
-11.27
Dividend yield
0.00%
52-week range
$2.83 – $8.37
Volume
1.33M
Avg. volume
1.17M

Price performance

FULC price history

1M range · 0 trading sessions · Daily adjusted prices

FULC does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest FULC news

The latest Smart Investors Daily articles mentioning FULC.

Stock researchCompany · Overview

FULC research

Overview

Company profile and research snapshot.

Company profile

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$20.71
Implied upside
—
Analysts
15
FULC recent ratings
DateFirmRatingTarget
Jun 3, 2026JP MorganUnderweight—
Jun 2, 2026Piper SandlerUnderweight—
Jun 2, 2026StifelHold—
Jun 2, 2026Truist SecuritiesHold—
Jun 2, 2026Leerink PartnersMarket Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 27, 2026

Slate Medicines Starts Migraine Treatment Study

By Karen Roman Slate Medicines Inc. said it dosed the first participant in Phase 1 of its clinical study evaluating SLTE-1009, the company’s subcutaneous antibody candidate for migraine treatment. Phase 1 single-and multiple-ascending dose is being conducted in Australia with topline safety data estimated by mid-2027, it stated. READ MORE Final Agenda: 2nd LA CorpGov […] The post Slate Medicines Starts Migraine Treatment Study appeared first on ExecEdge.

Yahoo · Aug 5, 2026

Fulcrum Therapeutics (FULC) Stock Sees Modest Fair Value Lift After Pociredir Exit

The updated analyst framework for Fulcrum Therapeutics lifts the Fair Value estimate from US$5.43 to US$5.83 per share. This shift in price target sits against a backdrop of sharply changed Street commentary after the decision to discontinue pociredir, with more focus on cash, restructuring and the ongoing review of options than on late stage development potential. Read on to see how this evolving narrative could matter for your own view on Fulcrum Therapeutics and how to track the next set...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By